Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Weekly digests, breaking news, and analyses from the world of psychedelic research
Eating disorders remain among psychiatry's most treatment-resistant conditions, with mortality rates exceeding those of any other mental illness. Emerging research suggests psychedelic-assisted therapy may offer unprecedented breakthroughs by targeting the underlying psychological mechanisms of disordered eating.
Colorado's Natural Medicine Act represents a watershed moment in psychedelic policy reform. This comprehensive guide examines the decriminalization framework, clinical research supporting psilocybin therapy, and what this means for patients and practitioners seeking evidence-based treatment options.
Eating disorders remain treatment-resistant despite conventional therapy, but emerging research suggests psychedelic-assisted therapy—including psilocybin, ketamine, and MDMA—may offer breakthrough mechanisms for recovery by promoting neuroplasticity, restoring reward processing, and healing underlying trauma.
While individual psychedelic therapy has dominated clinical research, group settings are emerging as a promising frontier in psychedelic-assisted treatment. Recent evidence suggests that shared therapeutic experiences may amplify healing while addressing accessibility challenges in modern mental healthcare.
Psychedelics fundamentally rewire the brain's communication patterns by dramatically reducing Default Mode Network activity and increasing neural entropy. Research reveals how compounds like psilocybin, LSD, and ketamine promote neuroplasticity and offer breakthrough treatments for treatment-resistant depression, PTSD, and addiction—mechanisms now being translated into clinical practice.
Microdosing has exploded in popular culture, but the scientific evidence is more nuanced than headlines suggest. We review the latest RCTs, placebo challenges, and what we actually know about sub-perceptual psilocybin doses.
As psychedelic-assisted therapy moves from research laboratories into clinical practice, mental health professionals face a critical question: what training is necessary to safely guide patients through these transformative experiences? This comprehensive guide explores the emerging landscape of therapist training programs, essential competencies, and evidence-based protocols reshaping psychiatric care.
Stanislav Grof fundamentally shaped modern psychedelic-assisted therapy through decades of rigorous research on consciousness exploration. His pioneering work bridged traditional psychiatry and transpersonal psychology, establishing frameworks that continue to guide contemporary clinical protocols.
Ibogaine has emerged as a controversial yet potentially transformative treatment for opioid addiction, with clinical observations suggesting rapid withdrawal symptom reduction and long-term abstinence benefits. Recent research examines both the therapeutic promise and safety concerns of this powerful psychedelic alkaloid.
Ketamine infusion therapy represents a paradigm shift in treating severe depression that hasn't responded to conventional antidepressants. Recent clinical trials demonstrate rapid onset of therapeutic effects within hours to days, offering hope to millions of patients with treatment-resistant depression worldwide.
Emerging neuroscience reveals that psychedelics fundamentally reshape brain structure and function through neuroplasticity. Recent studies demonstrate how substances like psilocybin and MDMA promote neural rewiring, offering unprecedented therapeutic potential for treatment-resistant conditions.
Emerging research suggests psilocybin-assisted therapy may revolutionize smoking cessation treatment, with early studies indicating unprecedented quit rates and neuroplastic changes that address the root causes of nicotine addiction.
Articles are drafted with AI assistance and editorially reviewed.